Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Hunterian Medicine LLC
Profile last edited on: 1/26/24      CAGE: 8HHR5      UEI: MCVJGPMKCAL1

Business Identifier: Addressing genetic diseases by correcting DNA mutations using innovative CRISPR delivery technology
Year Founded
2020
First Award
2022
Latest Award
2022
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

100 Pacific Street Apt 6
Cambridge, MA 02139
   (888) 486-8633
   info@hunterian.com
   www.hunterian.com
Location: Single
Congr. District: 07
County: Middlesex

Public Profile

Describing themselves as a gene-editing company, Hunterian Medicine is structured around unleashing what is described as the "full potential" of CRISPR. The firm's patented platform technology addresses what is called the "CRISPR delivery problem" by enabling efficient, on-target delivery through a single adeno-associated virus (AAV). Hunterian Medicine’s technology opens an immediate path to develop cures for a vast number of genetic disease

Extent of SBIR involvement

User Avatar
Phase I Awards
1
Phase II Awards
0
Conversion Rate
0.00%
Phase I Dollars
$320,000
Phase II Dollars
$0
Total Awarded
$320,000

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2023 1 NIH $350,000
Project Title: An early-intervention gene-editing therapeutic for Pulmonary Arterial Hypertension
2022 1 NIH $320,000
Project Title: Gene Therapy for Cystic Fibrosis Using Novel Compact Promoters

Key People / Management

  Vinod Jaskula-Ranga -- CEO

  Todd Hartman

  Vinod Jaskularanga -- Founder, President, and CEO,

  Robert Lorette -- Chief Licensing Officer & Vice President of Business Development

  Anand E Somayaji -- Chief Financial Officer

  Daniel Yu -- Scientist I, Assay Developmen

Company News

There are no news available.